Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: A Prospective Randomized Open Blinded End-Point (Probe) Study

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apixaban (Primary) ; Dalteparin sodium
Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
Focus Adverse reactions; Therapeutic Use
Acronyms Caravaggio

13 Dec 2022 Results of sub-analysis of the CARAVAGGIO trial, presented at the 64th American Society of Hematology Annual Meeting and Exposition
07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
05 Apr 2022 Results from Caravaggio and other study assessing whether antiangiogenics are associated with increased proportion of PE in oncological patients with VTE, published in the Thrombosis and Haemostasis

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com